Ambrosia Plasma relaunches - announces improvement in key ageing biomarkers
The Club interviews Jesse Karmazin, CEO, to find out more about the trial, the FDA warning, and the relaunch
Join the club for FREE to access the whole archive and other member benefits.
Biotechnology company focused on treating neurodegenerative and other age-related diseases
Aging is the dominant risk factor in degenerative diseases. Many of the pressing age-related and neurodegenerative diseases have a profound impact on patients and their caregivers, yet have very limited treatment options. Alkahest has embarked upon a simple but elegant approach to treat disorders of aging by capitalizing on the body’s own natural regulatory and communication mechanisms, leveraging the plasma proteome. The promise of this science, and the potential to make a difference to patients around the world, was the founding principle of Alkahest.
Alkahest’s therapeutic agents stem from a deep understanding of the changing plasma proteome in healthy aging and in age-related diseases. As we age, the majority of our proteins stay the same. But about 15% of our proteins change substantially as we age, or as we contend with disease. It’s these proteins, the chronokines, which inspire Alkahest science. By targeting chronokines, we develop clinical candidates that either increase or decrease the levels of circulating chronokines to promote innate and natural restorative biological processes or discourage pathological, degenerative processes in age-related diseases.
Visit website: http://www.alkahest.com/
Details last updated 09-Apr-2019
The Club interviews Jesse Karmazin, CEO, to find out more about the trial, the FDA warning, and the relaunch
Summary of “Turning back time with emerging rejuvenation Strategies” published in Nature Cell Biology
Many people believe lots of clinical trials of novel therapeutics targeting mechanisms of aging will start up in the next few years
More and more companies making greater and greater progress - 2021 could be an exciting year
This could be a cheap first generation rejuvenation treatment - but wait for clinical trials
With phase 2 study announced, hopes are up for end-stage renal disease sufferers
An interesting collection of interviews and white-papers with industry leaders
Plasma proteins to the rescue of good-old memories in Alzheimer's
Intriguing hint that this treatment may have potential for other age-related diseases
GDF11 is a protein in the blood, which can stimulate cell growth and repair
16 people with mild or moderate Alzheimer’s disease received weekly injections of young plasma. ...
Ambrosia (https://www.ambrosiaplasma.com/) young plasma trial is open to anyone 35 and older. Pa...